Voriconazole
As of the edition of 20 October 2026, Voriconazole is a small molecule: marketed, first approved in 2002 (EU).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Vfend
- First approved
- 19 March 2002 (EU)
- Approvals on record
- 18 in 7 regions
- Holder of the most recent approval
- Hikma Farmaceutica; 5 holders in all
- Registered trials
- 113, 16 stopped early
- Disease areas
- Infections; Blood and lymph; Cancer; Immune system; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 26 | 17 | 0 | 2 |
| Phase 1 | 27 | 19 | 3 | 3 |
| Phase 2 | 16 | 11 | 0 | 3 |
| Phase 3 | 23 | 17 | 0 | 4 |
| Phase 4 | 21 | 16 | 0 | 4 |
| All trials | 113 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant, Later holder and Lead sponsor of trials | 2002 to now |
| Hikma Pharmaceuticals | Acquired holder | 2025 to now |